Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Frequently asked questions
What sector does Cassava Sciences, Inc. ORD SHS (SAVA-RM) operate in?
Cassava Sciences, Inc. ORD SHS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cassava Sciences, Inc. ORD SHS (SAVA-RM) current stock price?
As of the latest data, Cassava Sciences, Inc. ORD SHS stock price is RUB 145.00, with a previous close of RUB 145.00.
What is Cassava Sciences, Inc. ORD SHS (SAVA-RM) current market capitalization?
Cassava Sciences, Inc. ORD SHS market cap is approximately 58.21 million.
What is Cassava Sciences, Inc. ORD SHS (SAVA-RM) Earnings Per Share (EPS)?
The trailing EPS is -RUB 148.33, and the forward EPS is -RUB 1.22.
Does Cassava Sciences, Inc. ORD SHS (SAVA-RM) pay dividends?
No. Cassava Sciences, Inc. ORD SHS does not pay a dividend.
What is Cassava Sciences, Inc. ORD SHS (SAVA-RM) beta (volatility) score?
Cassava Sciences, Inc. ORD SHS has a beta of 1.126, meaning its volatility is roughly in line with the market.